JanOne Issues September 2020 Shareholder Letter Updating Investors on Recent Pharma Asset Potential for Peripheral Artery DiseasePRNewsWire • 09/22/20
JanOne Selects Partner for Bottling and Labeling of JAN101 for Peripheral Artery Disease and Potential Covid-19 Clinical TrialsPRNewsWire • 08/28/20
JanOne Advances its Potential Peripheral Artery Disease and Covid-19 Vascular Inflammation Treatment Towards Trial ReadinessPRNewsWire • 08/26/20
JanOne Inc. (JAN) CEO Tony Isaac on Drug Candidate JAN101 - Telebriefing and Corporate Update Call TranscriptSeeking Alpha • 08/26/20
JanOne to Host Telebriefing to Discuss Drug Candidate JAN101 for Treatment of Peripheral Artery Disease (PAD) and Potential Applications for COVID-19 Vascular ComplicationsPRNewsWire • 08/21/20
JanOne Completes Stable Formulation of JAN101 in Preparation for Its First GMP Manufacturing Batch to Support Upcoming Clinical TrialsPRNewsWire • 08/11/20
JanOne Engages CATO SMS, a World-Leading CRO, to Assist in the Development of JAN101 to Treat COVID-19 Vascular ComplicationsPRNewsWire • 08/06/20
JanOne bolsters its scientific advisory board with two leaders in the medical field for vascular regeneration and interventional painPRNewsWire • 07/30/20
Dr. Rakesh Patel, internationally recognized scientist in nitric oxide and redox biology, and Dr. Timothy Ness, a pain mechanisms and medication expert, join JanOne's Scientific Advisory BoardPRNewsWire • 07/08/20
One of the nation's most renowned pain experts, Dr. Edgar Ross, joins JanOne's Scientific Advisory BoardPRNewsWire • 06/30/20
JanOne taps distinguished chemist Dr. Doug Flanagan as chief formulation advisorPRNewsWire • 06/25/20